טנסופריל 5 מ"ג Israel - Ibrani - Ministry of Health

טנסופריל 5 מ"ג

merck sharp & dohme israel ltd - lisinopril as dehydrate 5 mg - tablets - lisinopril - hypertension: tensopril is indicated for the treatment of essential hypertension and renovascular hypertension.tensopril may be used alone as initial therapy, or concomitantly with other classes of antihypertensive agents. congestive heart failure: tensopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. acute myocardial infarction: tensopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction to improve survival.

דיובאן 80 מג טבליות מצופות Israel - Ibrani - Ministry of Health

דיובאן 80 מג טבליות מצופות

novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

דיובאן 160 מג טבליות מצופות Israel - Ibrani - Ministry of Health

דיובאן 160 מג טבליות מצופות

novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

דיובאן   40 מג טבליות מצופות Israel - Ibrani - Ministry of Health

דיובאן 40 מג טבליות מצופות

novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan significantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

וקטור 40 Israel - Ibrani - Ministry of Health

וקטור 40

unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

וקטור 160 Israel - Ibrani - Ministry of Health

וקטור 160

unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ואלסרטן דקסל 40 Israel - Ibrani - Ministry of Health

ואלסרטן דקסל 40

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ואלסרטן דקסל 80 Israel - Ibrani - Ministry of Health

ואלסרטן דקסל 80

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ואלסרטן דקסל 160 Israel - Ibrani - Ministry of Health

ואלסרטן דקסל 160

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ליפיטור 40 מג Israel - Ibrani - Ministry of Health

ליפיטור 40 מג

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - טבליות מצופות פילם - atorvastatin as calcium 40 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190